Recruiting
Phase 2

Observational Study

Sponsor:

The Cooper Health System

Code:

NCT00254319

Conditions

Untreated Advanced Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avastin, Alimta

Study Details

Brief summary:

Avastin is a novel antiangiogenic agent that has recently been shown to improve response rates and survival of patients with advanced nonsquamous non-small cell lung cancer when added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely incorporated into the treatment of these patients. Alimta is a recently approved chemotherapeutic that has shown activity against non-small cell lung cancer when given alone and in combination with carboplatin, has a favorable toxicity profile andrequires only a brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin, Alimta, and Carboplatin administered as front-line therapy to patients with advanced nonsquamous non-small cell lung cancer.

Conditions

Untreated Advanced Non-Small Cell Lung Cancer

Study ID

NCT00254319

Status verified date

Nov, 2005

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any major surgical procedures within 28 days prior to my starting treatment.

I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox for treatment of medical conditions. I do not have serious wound healing problems. I have not received any previous treatment, except radiation therapy for my disease.

Exclusion Criteria:

-

Study Design

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

Avastin, Alimta

Central Contacts and Locations

Central contacts

Elta Field

856-325-6759field-elta@cooperhealth.edu

Locations

The CINJ at Cooper University Hospital

Recruiting

Voorhees, New Jersey, United States, 08043

Principal Investigator:

James Stevenson, MD

More Information

Sponsor

The Cooper Health System

Last update posted

Nov 16, 2005

Last verified

Nov, 2005

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by The Cooper Health System on 2005-11-16.